Autologous haematopoietic stem-cell transplantation versus bortezomib–melphalan–prednisone, with or without bortezomib–lenalidomide–dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study

Autor: Cavo, Michele *, Gay, Francesca, Beksac, Meral, Pantani, Lucia, Petrucci, Maria Teresa, Dimopoulos, Meletios A, Dozza, Luca, van der Holt, Bronno, Zweegman, Sonja, Oliva, Stefania, van der Velden, Vincent H J, Zamagni, Elena, Palumbo, Giuseppe A, Patriarca, Francesca, Montefusco, Vittorio, Galli, Monica, Maisnar, Vladimir, Gamberi, Barbara, Hansson, Markus, Belotti, Angelo, Pour, Ludek, Ypma, Paula, Grasso, Mariella, Croockewit, Alexsandra, Ballanti, Stelvio, Offidani, Massimo, Vincelli, Iolanda D, Zambello, Renato, Liberati, Anna Marina, Andersen, Niels Frost, Broijl, Annemiek, Troia, Rossella, Pascarella, Anna, Benevolo, Giulia, Levin, Mark-David, Bos, Gerard, Ludwig, Heinz, Aquino, Sara, Morelli, Anna Maria, Wu, Ka Lung, Boersma, Rinske, Hajek, Roman, Durian, Marc, von dem Borne, Peter A, Caravita di Toritto, Tommaso, Zander, Thilo, Driessen, Christoph, Specchia, Giorgina, Waage, Anders, Gimsing, Peter, Mellqvist, Ulf-Henrik, van Marwijk Kooy, Marinus, Minnema, Monique, Mandigers, Caroline, Cafro, Anna Maria, Palmas, Angelo, Carvalho, Susanna, Spencer, Andrew, Boccadoro, Mario, Sonneveld, Pieter
Zdroj: In The Lancet Haematology June 2020 7(6):e456-e468
Databáze: ScienceDirect